Breast Cancer
Conditions
Interventions
Gold Standard:Gold standard is the paraffin pathological results after ALND. Reference standard is Expert Consensus and Technical Guidelines for Sentinel Lymph Node Biopsy of Early Breast Cancer with
lymph 
biopsy
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) women, age at 18-70 years; (2) primary invasive breast adenocarcinoma confirmed by physical examination, breast color Doppler ultrasound, mammography, MRI evaluation, and hollow needle histological examination; (3) those who have not previously received treatment for breast cancer, agree to participate in the study, and have good compliance; (4) the Eastern Cooperative Oncology Group (ECOG) performance status grade 0-2; (5) before treatment, the results of hematological and biochemical examinations should meet the following conditions: white blood cells >= 4.0 x 10^9/L, absolute neutrophil count >= 1.5 x 10^9/L, platelet count >= 100 x 10^9/L, hemoglobin >= 90 g/L, glutathione transaminase, alanine transaminase <= 1.5 x upper limit of normal, creatinine <= 1.5 x upper limit of normal, total bilirubin <= 1.5 x upper limit of normal; (6) provision of written informed consent.
Exclusion criteria
Exclusion criteria: (1) serious heart, liver or kidney diseases; (2) lactating or pregnant women; (3) patients with confirmed distant metastasis of breast cancer; (4) patients with sensory or motor neuropathy, or those diagnosed with psychiatric disorder; (5) patients with confirmed cardiovascular diseases, serious concomitant diseases or active infections including known human immunodeficiency virus infection; (6) patients with history of other cancers; (7) patients allergic to drugs and excipients involved in tracers and neoadjuvant chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| False negative rate of sentinel lymph node biopsy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between each influential factor and the results of sentinel lymph node biopsy after neoadjuvant chemotherapy;Adverse events; | — |
Countries
China
Contacts
Public ContactBo Chen
The First Affiliated Hospital of China Medical University
Outcome results
None listed